OriGene Pioneers High-Density Protein Microarray Chip for Optimal Validation of Antibody Specificity

OriGene Technologies, Inc., a gene-centric life sciences company known for its development cDNA clones, human full length proteins, antibodies, and other molecular tools for multiplex research introduces its major breakthrough technology High-Density Protein Microarray Chip for the quality control of its (TrueMAB™) monoclonal antibodies.

The new chip enables OriGene to screen monoclonal antibodies against 10,000 human proteins to provide the most specific monoclonal antibodies.The antibodies validated with the OriGene High-Density Protein Microarray Chip will enable IVD manufacturers to develop the most accurate and specific immunoassays for clinical applications.

"We are extremely pleased with our progress in achieving this significant advancement in our Genome-Wide High Throughput Antibody Development Program. Better measurement equates to better science. We are confident this technology will advance research and the resulting analysis with validation superior to any other antibody manufacturer," commented Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.

To learn more about OriGene TrueMABs, visit OriGene at the upcoming AACC in Atlanta, GA from July 24 - 26 at Booth #4254 or go to the company article page.